BCA
AERI
Benchmark Capital Advisors’s Aerie Pharmaceuticals, Inc. AERI Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | $902K | Sell |
25,000
-8,500
| -25% | -$307K | 0.9% | 38 |
|
|
2018
Q3 | $2.06M | Sell |
33,500
-1,500
| -4% | -$92.3K | 1.55% | 16 |
|
|
2018
Q2 | $2.36M | Buy |
35,000
+5,400
| +18% | +$365K | 1.79% | 13 |
|
|
2018
Q1 | $1.61M | Hold |
29,600
| – | – | 1.27% | 22 |
|
|
2017
Q4 | $1.77M | Buy |
29,600
+200
| +0.7% | +$12K | 1.38% | 23 |
|
|
2017
Q3 | $1.43M | Buy |
29,400
+16,000
| +119% | +$778K | 1.11% | 27 |
|
|
2017
Q2 | $704K | Sell |
13,400
-35,925
| -73% | -$1.89M | 0.56% | 50 |
|
|
2017
Q1 | $2.24M | Sell |
49,325
-11,800
| -19% | -$535K | 1.77% | 18 |
|
|
2016
Q4 | $2.31M | Sell |
61,125
-2,075
| -3% | -$78.6K | 1.92% | 16 |
|
|
2016
Q3 | $2.39M | Buy |
63,200
+8,500
| +16% | +$321K | 1.8% | 15 |
|
|
2016
Q2 | $963K | Buy |
54,700
+4,200
| +8% | +$73.9K | 0.79% | 42 |
|
|
2016
Q1 | $614K | Sell |
50,500
-5,300
| -9% | -$64.4K | 0.54% | 54 |
|
|
2015
Q4 | $1.36M | Sell |
55,800
-500
| -0.9% | -$12.2K | 1.15% | 28 |
|
|
2015
Q3 | $999K | Buy |
56,300
+900
| +2% | +$16K | 0.81% | 42 |
|
|
2015
Q2 | $978K | Buy |
55,400
+37,700
| +213% | +$666K | 0.69% | 46 |
|
|
2015
Q1 | $555K | Sell |
17,700
-31,200
| -64% | -$978K | 0.37% | 71 |
|
|
2014
Q4 | $1.43M | Buy |
48,900
+1,900
| +4% | +$55.4K | 0.96% | 30 |
|
|
2014
Q3 | $972K | Buy |
+47,000
| New | +$972K | 0.67% | 49 |
|